In this issue:
BCMA-targeted CAR T-cell therapy in refractory lupus nephritis
GPRC5D-targeted CAR T-cell therapy in R/R multiple myeloma
META 10-19 in R/R B-ALL
Real-world axi-cel vs. tisa-cel vs. liso-cel in R/R LBCL
External validation of the CARHEMATOTOX score in real-world R/R LBCL
MRD status & response to axi-cel in R/R LBCL
Epcoritamab vs. axi-cel in CAR T-cell-eligible/ naïve R/R DLBCL
2025 EBMT recommendations on CAR-T & HCT
Therapies in relapsed/refractory DLBCL after CAR T-cell therapy
Real-world brexu-cel in R/R MCL
Please login below to download this issue (PDF)